By: IPP Bureau
Last updated : April 11, 2026 7:37 am
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
Zydus Lifesciences Limited has reported an improvement in its overall Environmental, Social and Governance (ESG) score, with ESG Risk Assessments and Insights Limited (ESGRAIL) assigning the company a rating of 68 for FY26, up from 66 in the previous year.
The disclosure, made under Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR), stated that the company received the ESG report via email on April 9, 2026.
Importantly, Zydus clarified that it did not engage ESGRAIL for this assessment, and that the SEBI-registered ESG rating provider had independently prepared the report using publicly available information.
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker, which has been sharpening its focus on sustainability, governance standards, and responsible business practices across global operations.
The company submitted the intimation to both BSE (Code: 532321) and NSE (Symbol: ZYDUSLIFE), reinforcing growing investor attention on ESG-linked disclosures in the pharmaceutical sector.